Axtria’s Agentic AI Platform Delivers Speed, Power, and Freedom of Choice
Axtria Inc., the AI-first data analytics innovator known for transforming life sciences, just unleashed the next generation of Axtria InsightsMAx. Now called Axtria InsightsMAx.ai, this groundbreaking platform is powered by agentic AI and fundamentally changes how life sciences organisations harness artificial intelligence. Axtria InsightsMAx.ai is a flexible, enterprise-grade infrastructure that accelerates experimentation, deployment, and returns on investment. Through a robust suite of more than 30 life sciences-specific agents, applications, and APIs, pharmaceutical companies can finally solve the critical “last mile” problem in AI implementation. “Axtria InsightsMAx.ai represents a paradigm shift from incremental AI improvements to true business transformation,” said Lokesh Jindal, head of products at Axtria. “Axtria InsightsMAx.ai serves as essential infrastructure—the plumbing, if you will—that makes agentic AI implementation practical, scalable, and measurable. While others focus on isolated use cases, we’ve built the interconnected system that enables life sciences companies to rapidly test, deploy, and scale AI innovation across their entire value chain.” Companies worldwide still face significant barriers to scaling AI, and these challenges are particularly pronounced in the life sciences sector. Generic AI implementations struggle with the specialised terminology in the industry; siloed and fragmented systems prevent organisations from uncovering key insights; healthcare regulations limit the scope of generic AI systems; connecting solutions to custom data sources can be tricky; and not to mention, the talent gap among employee pools. Axtria InsightsMAx.ai addresses each of these hurdles, offering companies complete freedom of choice. Through the robust library of agents, life sciences companies can choose the specific AI agents they need, rather than relying on a generic AI implementation. These domain-specific, autonomous agents are designed expressly for life sciences workflows, and each is ready for immediate deployment. These agents don’t just automate tasks, they transform entire processes by intelligently orchestrating workflows, predicting outcomes, and continuously improving performance through domain-specific learning. Even better, the agents are fully compatible with regulatory restrictions and demands. The simplicity of specific agents enables users to make data-driven decisions quickly, without needing to learn coding. But that’s only the beginning. Axtria InsightsMAx.ai also puts life sciences companies directly in the driver’s seat. They can go into the included workbench and experiment with the full range of agents, apps, and APIs to see what works for them. They can then take that custom-built workflow and seamlessly scale it up to full use. Axtria InsightsMAx.ai allows enterprises to play in the workbench environment and find the solution that works best for them, without wasting time or resources on unnecessary features. “What sets our platform apart is its ability to serve as both the experimental sandbox and the production highway for agentic AI,” said Navdeep Chadha, chief technology officer at Axtria. “Life sciences companies can start small, proving value in controlled environments, then seamlessly scale successful innovations across their organisation without rebuilding infrastructure. This dramatically compresses the time from concept to enterprise-wide deployment from years to months or even weeks.” Once experimentation is complete, Axtria InsightsMAx.ai lets companies quickly build out their innovation roadmap, moving from concept to enterprise deployment through agent orchestrations, deployment frameworks, and, critically, through continuous optimisation, ensuring the solution remains agile. The library of agents in Axtria InsightsMAx.ai is already proving itself among major life sciences firms. It is now operational at six of the top ten global pharmaceutical companies, delivering measurable business outcomes, including greater than 90% decision accuracy, more than 75% faster speed to insights, and a 40% reduction in operational costs. On the human side of things, Axtria InsightsMAx.ai has enabled ten times faster onboarding for new products, markets, and teams. The innovative Axtria InsightsMAx.ai platform leverages over 14 years of pharmaceutical-specific data science expertise and proprietary semantic models that understand the nuanced relationships in life sciences data. The platform was developed in partnership with Genloop, featuring domain-tuned large language models that deliver superior performance with enhanced control and transparency. “The pharmaceutical industry faces unique challenges that generic AI solutions simply cannot address effectively,” added Chadha. “Our platform combines deep domain knowledge with cutting-edge AI capabilities, creating a purpose-built system that understands the complex interplay of scientific, commercial, and regulatory factors that drive life sciences business transformation.” For more information, check out the Axtria InsightsMAx.ai website here, or reach out to an Axtria representative today for a one-on-one demonstration of how this revolutionary, flexible platform turns your company’s AI ambitions into unimagined outcomes.
New Agentic AI Platform from Axtria Delivers Speed, Power, and Freedom of Choice to Life Sciences Companies
New Agentic AI Platform from Axtria Delivers Speed, Power, and Freedom of Choice to Life Sciences Companies
["agent ai", "AI (Artificial Intelligence)"]
["data science", "agentic AI", "artificial intelligence", "agent orchestration", "agent ai", "AI", "autonomous agents", "ML", "RAG", "analytics", "edge AI", "AI (Artificial Intelligence)"]
["AI", "artificial intelligence", "ML", "data science", "analytics", "agentic AI", "agent orchestration", "edge AI", "RAG", "autonomous agents"]
Supreeth is an engineering graduate who is curious about the world of artificial intelligence and loves to write stories on how it is solving problems and shaping the future of humanity.